(VIANEWS) – DHT Holdings (DHT), Taiwan Semiconductor (TSM), Agree Realty Corporation (ADC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. DHT Holdings (DHT)
42.1% sales growth and 18.39% return on equity
DHT Holdings, Inc., through its subsidiaries, owns and operates crude oil tankers primarily in Monaco, Singapore, Oslo, and Norway. As of March 17, 2021, it had a fleet of 28 very large crude carriers with a capacity of 8,660,835 deadweight tons. The company was founded in 2005 and is headquartered in Hamilton, Bermuda.
Earnings Per Share
As for profitability, DHT Holdings has a trailing twelve months EPS of $1.14.
PE Ratio
DHT Holdings has a trailing twelve months price to earnings ratio of 9.46. Meaning, the purchaser of the share is investing $9.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.39%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
DHT Holdings’s EBITDA is 28.3.
Moving Average
DHT Holdings’s worth is above its 50-day moving average of $10.26 and way higher than its 200-day moving average of $9.57.
2. Taiwan Semiconductor (TSM)
25% sales growth and 26% return on equity
Taiwan Semiconductor Manufacturing Company Limited, together with its subsidiaries, manufactures, packages, tests, and sells integrated circuits and other semiconductor devices in Taiwan, China, Europe, the Middle East, Africa, Japan, the United States, and internationally. It provides complementary metal oxide silicon wafer fabrication processes to manufacture logic, mixed-signal, radio frequency, and embedded memory semiconductors. The company also offers customer support and engineering services, as well as manufactures masks. Its products are used in high performance computing, smartphone, Internet of things, automotive, and digital consumer electronics. The company was incorporated in 1987 and is headquartered in Hsinchu City, Taiwan.
Earnings Per Share
As for profitability, Taiwan Semiconductor has a trailing twelve months EPS of $5.17.
PE Ratio
Taiwan Semiconductor has a trailing twelve months price to earnings ratio of 22.31. Meaning, the purchaser of the share is investing $22.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26%.
Moving Average
Taiwan Semiconductor’s value is way higher than its 50-day moving average of $100.45 and way higher than its 200-day moving average of $94.91.
Sales Growth
Taiwan Semiconductor’s sales growth for the next quarter is 25%.
Volume
Today’s last reported volume for Taiwan Semiconductor is 2651450 which is 75.36% below its average volume of 10762900.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Taiwan Semiconductor’s EBITDA is 1.03.
Previous days news about Taiwan Semiconductor(TSM)
- According to Zacks on Tuesday, 30 January, "The government is spending billions to attract semiconductor giants like Taiwan Semiconductor Manufacturing (TSM Quick QuoteTSM – Free Report) as it tries to regain its status as a major semiconductor power amid rising tensions."
3. Agree Realty Corporation (ADC)
14.4% sales growth and 3.38% return on equity
Earnings Per Share
As for profitability, Agree Realty Corporation has a trailing twelve months EPS of $1.7.
PE Ratio
Agree Realty Corporation has a trailing twelve months price to earnings ratio of 35.98. Meaning, the purchaser of the share is investing $35.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.38%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 24.3%, now sitting on 509.86M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Agree Realty Corporation’s EBITDA is 65.15.
Sales Growth
Agree Realty Corporation’s sales growth is 21.2% for the present quarter and 14.4% for the next.
Moving Average
Agree Realty Corporation’s worth is above its 50-day moving average of $60.49 and under its 200-day moving average of $62.19.
4. Exelixis (EXEL)
13.2% sales growth and 3.8% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.29.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 75.48. Meaning, the purchaser of the share is investing $75.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Exelixis’s EBITDA is -521.35.
5. Quanta Services (PWR)
11.9% sales growth and 12.7% return on equity
Quanta Services, Inc. provides specialty contracting services in the United States, Canada, Australia, Latin America, and internationally. Its Electric Power Infrastructure Services segment designs, installs, upgrades, repairs, and maintains electric power transmission and distribution infrastructure, and substation facilities, as well as provides other engineering and technical services; designs, installs, maintains, and repairs commercial and industrial wiring; and operates a postsecondary educational institution. It also offers emergency restoration services, including the repair of infrastructure damaged by inclement weather; installation, maintenance, and upgrade of electric power infrastructure; and installation of smart grid technologies on electric power networks. In addition, this segment provides services related to development of solar, wind, and various natural gas generation facilities, as well as related switchyards and transmission infrastructure; and construction of electric power generation facilities. The company's Pipeline and Industrial Infrastructure Services segment designs, installs, repairs, and maintains pipeline transmission and distribution systems, gathering systems, production systems, storage systems, and compressor and pump stations, as well as offers related trenching, directional boring, and mechanized welding services; and designs, installs, and maintains fueling systems, and water and sewer infrastructure. This segment also provides pipeline protection, integrity testing, and rehabilitation and replacement, as well as pipeline support systems, and related structures and facilities fabrication services; and high-pressure and critical-path turnaround, electrical, piping, fabrication, and storage tank services. It serves electric power, energy, and communications companies, as well as commercial, industrial, and governmental entities. The company was founded in 1997 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Quanta Services has a trailing twelve months EPS of $4.69.
PE Ratio
Quanta Services has a trailing twelve months price to earnings ratio of 41.86. Meaning, the purchaser of the share is investing $41.86 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.7%.
Sales Growth
Quanta Services’s sales growth is 17.2% for the ongoing quarter and 11.9% for the next.
Moving Average
Quanta Services’s value is below its 50-day moving average of $199.34 and higher than its 200-day moving average of $188.73.
Volume
Today’s last reported volume for Quanta Services is 870208 which is 25.18% below its average volume of 1163150.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Quanta Services’s EBITDA is 56.82.
6. Humana (HUM)
8.1% sales growth and 15.68% return on equity
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of PBM business. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Earnings Per Share
As for profitability, Humana has a trailing twelve months EPS of $19.99.
PE Ratio
Humana has a trailing twelve months price to earnings ratio of 18.86. Meaning, the purchaser of the share is investing $18.86 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.68%.
7. Restaurant Brands International (QSR)
7.5% sales growth and 30.52% return on equity
Restaurant Brands International Inc. operates as a quick-service restaurant company in Canada, the United States, and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and other food products. It is also involved in owning and franchising BK, a fast-food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, French fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana-style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS quick service restaurants that offer meats and cheese, chopped salads, chili and soups, signature and other sides, soft drinks, and local specialties. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Restaurant Brands International has a trailing twelve months EPS of $2.9.
PE Ratio
Restaurant Brands International has a trailing twelve months price to earnings ratio of 27.03. Meaning, the purchaser of the share is investing $27.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.52%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Dec 19, 2023, the estimated forward annual dividend rate is 2.2 and the estimated forward annual dividend yield is 2.86%.
Volume
Today’s last reported volume for Restaurant Brands International is 63165 which is 94.97% below its average volume of 1257360.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Restaurant Brands International’s EBITDA is 56.01.
8. Surgery Partners (SGRY)
7.2% sales growth and 3.88% return on equity
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Earnings Per Share
As for profitability, Surgery Partners has a trailing twelve months EPS of $-0.33.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.88%.
Moving Average
Surgery Partners’s worth is higher than its 50-day moving average of $31.85 and below its 200-day moving average of $34.20.
Volume
Today’s last reported volume for Surgery Partners is 739593 which is 25.66% below its average volume of 994898.
Sales Growth
Surgery Partners’s sales growth is 4.9% for the ongoing quarter and 7.2% for the next.
Previous days news about Surgery Partners(SGRY)
- According to Zacks on Wednesday, 31 January, "Some better-ranked stocks from the broader medical space are SiBone (SIBN Quick QuoteSIBN – Free Report) , Surgery Partners (SGRY Quick QuoteSGRY – Free Report) and Haemonetics (HAE Quick QuoteHAE – Free Report) , each carrying a Zacks Rank #2 (Buy). "
